Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Merestinib |
Trade Name | |
Synonyms | LY2801653|LY-2801653 |
Drug Descriptions |
Merestinib (LY2801653) inhibits several receptor tyrosine kinases including MET, MST1R (RON), AXL, MERTK, TYRO3, ROS1 fusions, PDGFRA, FLT3, TEK, DDR1/2, MKNK1/2, and NTRK1/2/3 with greatest activity against NTRK1, and may result in decreased tumor growth (PMID: 23275061, PMID: 24305878, PMID: 29568395, PMID: 32537847). |
DrugClasses | AXL Inhibitor 30 DDR1 Inhibitor 10 DDR2 inhibitor 7 FLT3 Inhibitor 69 MET Inhibitor 59 RON Inhibitor 11 ROS1 Inhibitor 20 Trk Receptor Inhibitor (Pan) 32 TYRO3 Inhibitor 8 |
CAS Registry Number | 1206799-15-6 |
NCIT ID | C95729 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Capmatinib + Merestinib | Capmatinib Merestinib | 0 | 0 |
LY2874455 + Merestinib | LY2874455 Merestinib | 0 | 1 |
Merestinib | Merestinib | 0 | 4 |
Merestinib + Ramucirumab | Merestinib Ramucirumab | 0 | 1 |